Short Interest in Exelixis Declines By 4.7% (EXEL)
Shares of Exelixis (NASDAQ:EXEL) saw a significant decrease in short interest in August. As of August 15th, there was short interest totalling 48,189,006 shares, a decrease of 4.7% from the July 31st total of 50,541,127 shares, Analyst Ratings Network reports. Currently, 25.5% of the company’s stock are sold short. Based on an average trading volume of 2,285,198 shares, the short-interest ratio is presently 21.1 days.
A number of research firms have recently commented on EXEL. Analysts at Piper Jaffray downgraded shares of Exelixis from an “overweight” rating to a “neutral” rating in a research note on Tuesday. They now have a $2.50 price target on the stock, down previously from $11.00. Analysts at Cowen and Company downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $6.00.
Shares of Exelixis (NASDAQ:EXEL) opened at 1.85 on Wednesday. Exelixis has a one year low of $1.84 and a one year high of $8.41. The stock has a 50-day moving average of $3.98 and a 200-day moving average of $4.22. The company’s market cap is $361.0 million.
Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Thursday, July 31st. The company reported ($0.38) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.39) by $0.01. The company had revenue of $6.56 million for the quarter, compared to the consensus estimate of $5.66 million. During the same quarter in the prior year, the company posted ($0.34) earnings per share. The company’s quarterly revenue was down 44.7% on a year-over-year basis. Analysts expect that Exelixis will post $-1.54 EPS for the current fiscal year.
Exelixis, Inc (NASDAQ:EXEL) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.